MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/20.06.25 Share Price

Warrant

DE000ME1Z113

Market Closed - Börse Stuttgart 12:47:57 06/07/2024 am IST
0.27 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/PUT/NOVO NORDISK ADR B/100/0.1/20.06.25
Current month+3.85%
1 month-3.57%
Date Price Change
05/24/05 0.27 0.00%
04/24/04 0.27 -6.90%
03/24/03 0.29 +7.41%
02/24/02 0.27 +12.50%
01/24/01 0.24 -7.69%

Delayed Quote Börse Stuttgart

Last update July 06, 2024 at 12:47 am IST

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1Z11
ISINDE000ME1Z113
Date issued 12/10/2023
Strike 100 $
Maturity 20/06/2025 (350 Days)
Parity 10 : 1
Emission price 1.6
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.83
Lowest since issue 0.229
Delta-0.1x
Omega 4.920
Premium31.89x
Gearing47.78x
Moneyness 0.7020
Difference Strike -42.37 $
Difference Strike %-42.37%
Spread 0.01
Spread %3.57%
Theoretical value 0.2750
Implied Volatility 36.95 %
Total Loss Probability 82.06 %
Intrinsic value 0.000000
Present value 0.2750
Break even 97.02 €
Theta-0.01x
Vega0.02x
Rho-0.01x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus